Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma
about
Therapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: Review of the present evidence and future directionA single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastomaA phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study.Histone H3 phosphorylation in GBM: a new rational to guide the use of kinase inhibitors in anti-GBM therapy.Variant allele frequency enrichment analysis in vitro reveals sonic hedgehog pathway to impede sustained temozolomide response in GBMA Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With GlioblastomaProgrammed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed GlioblastomaAssociation of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials.Relationship of glioblastoma multiforme to the subventricular zone is associated with survival.Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme.Combining molecular targeted agents with radiation therapy for malignant gliomasAutotaxin Inhibition with PF-8380 Enhances the Radiosensitivity of Human and Murine Glioblastoma Cell LinesImpact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current EvidenceAKT/GSK3β Signaling in Glioblastoma.Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?Antiangiogenic therapies in glioblastoma multiforme.Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach.Targeted therapy in gliomas.State of the art and perspectives in the treatment of glioblastoma.Predictive biomarkers investigated in glioblastoma.Clipping the Wings of Glioblastoma: Modulation of WNT as a Novel Therapeutic Strategy.Inhibition of polo-like kinase 1 induces cell cycle arrest and sensitizes glioblastoma cells to ionizing radiation.Therapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma.Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen.Identifying Voxels at Risk for Progression in Glioblastoma Based on Dosimetry, Physiologic and Metabolic MRI.Neuro-oncology: Glioblastoma--community adjusts to new standard of care.Glioblastoma Treatments: An Account of Recent Industrial DevelopmentsContemporary Updates on Clinical Trials of Antiangiogenic Agents in the Treatment of Glioblastoma MultiformeLate toxicity in long-term survivors from a phase 2 study of concurrent radiation therapy, temozolomide and valproic acid for newly diagnosed glioblastoma
P2860
Q26774717-5745DD8E-06EB-4541-AD71-90D5FB3E4FF2Q33413997-E8DCB722-17EF-406F-B33E-D5A1F536670BQ33418912-FC903FEA-512A-4190-B67F-C5C9A6B61F0FQ34698607-DB1817DF-0E96-47AE-8ADB-7A45DE5C832EQ34990583-B22CF469-A7BF-4D16-AA30-30CF9F5D2C19Q35701142-A2F786F9-C16C-45E8-8DC0-2773C62D14BAQ35815273-C4F2F78E-796A-4009-8AC7-7E826A9BD38EQ35862544-D2FAC0EC-E74A-4898-B4FD-B2D4A5179F3DQ36427538-C9E793BA-E751-49BB-8F31-4178520F51D1Q36500389-7667B851-582D-47A5-BDE0-D0B567401E47Q36713503-78853940-A575-4932-B165-772E0D7ACF7BQ37099594-BE9D1BE1-B688-4AE7-AB4D-D2A5A3C09A30Q37177631-FEDBA054-C9BD-44D0-9BC7-0A6B382C0F8AQ37603194-7D4C3061-CE7C-49E5-A04F-AF73298429E5Q37710163-F67BA4CE-C680-4CC6-81BF-24909C7CC2C8Q37993124-99CCBA4B-3B25-4BC3-8B8B-DF91A1F60752Q38010802-C1A71379-DCF4-453A-8B47-15AB527FAD9DQ38108186-0D9F09E8-1716-408E-8AC1-5976FC91EFDEQ38186656-2F34E6FF-8B58-4844-A66E-D1F718BCBE80Q38233067-DAEC10DB-98D9-4C78-A0FB-55A92E76AB52Q38237337-C0E61250-CF62-4041-822E-462D8B0C0A06Q38775522-093D5E15-3D2C-4BEC-9257-94C468E1634FQ39146648-B6FE8D6D-59D0-4B48-85FB-AF99B3CA961CQ39236500-E603F71B-57DF-443E-A763-357BD5EB8E3EQ39439133-59B6F8E5-EF27-4FA0-A11E-C6561D4FF282Q40116790-B630AC84-A470-4FEA-92E3-3200DD6830A3Q48607482-A1C706E2-CA1E-4721-92A0-8C849F4D38D0Q57111067-170DDFA1-424F-4856-BC2A-CD0B860ABD04Q57141680-3244C47A-D3DB-4A49-A559-F07D94F3CEC1Q58571031-F65E6622-0153-4A50-81FF-68FA91656F05
P2860
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Phase II and pharmacogenomics ...... oma multiforme and gliosarcoma
@ast
Phase II and pharmacogenomics ...... oma multiforme and gliosarcoma
@en
type
label
Phase II and pharmacogenomics ...... oma multiforme and gliosarcoma
@ast
Phase II and pharmacogenomics ...... oma multiforme and gliosarcoma
@en
prefLabel
Phase II and pharmacogenomics ...... oma multiforme and gliosarcoma
@ast
Phase II and pharmacogenomics ...... oma multiforme and gliosarcoma
@en
P2093
P2860
P356
P1433
P1476
Phase II and pharmacogenomics ...... oma multiforme and gliosarcoma
@en
P2093
Angelina Nicole
Donald E Thornton
Emily Hsieh
Jennifer Clarke
Joseph F Costello
Kathleen R Lamborn
Maria Hristova-Kazmierski
Mei-Yin Polley
Michael D Prados
Nicholas Butowski
P2860
P304
P356
10.1093/NEUONC/NOR130
P577
2011-09-06T00:00:00Z